A groundbreaking development in heart health has been announced with the introduction of a new drug targeting Lipoprotein(a) or Lp(a), a genetically influenced form of cholesterol associated with an increased risk of heart attacks and strokes.
Professor Stephen Nicholls of Monash University's Victorian Heart Institute and Victorian Heart Hospital led the research, presenting the findings at the European Society of Cardiology Congress. Lp(a), Muvalaplin demonstrated a reduction of up to 65% in Lp(a) levels, offering a potential game-changing solution for addressing this previously untreatable cardiovascular risk factor.
For more information visit:
https://medicalxpress.com/news/2023-08-drugs-previously-untreatable-life-threatening-bad.html
